Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Update

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 2,033 shares, a decrease of 61.2% from the June 15th total of 5,246 shares. Based on an average trading volume of 80,643 shares, the short-interest ratio is currently 0.0 days.

Algernon Pharmaceuticals Price Performance

AGNPF stock opened at $0.33 on Monday. The firm’s 50-day simple moving average is $0.31 and its 200 day simple moving average is $0.14. Algernon Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $0.64.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).